AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01763983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
Study NCT02336048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
Study NCT03778398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic music therapy
Description: Customized piano training
Study NCT02552095 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PKR
Study NCT05912491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasonography
Description: Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
Study NCT02202967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
Study NCT02202967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains lactose granules
Study NCT02015949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
Study NCT02015949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily placebo tablet for two weeks
Study NCT04257409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical intervention by exercise
Description: 12 week lasting exercise intervention
Study NCT02923531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: X4P-001 will be administered as per the dose and schedule specified in the arm.
Study NCT02923531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as per the dose and schedule specified in the arm.
Study NCT03287323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proactive Palliative Care
Description: In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
Study NCT03123913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
Study NCT03123913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
Study NCT05563740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial
Description: Daily telephone calls with two sessions of Brief Interventions for alcohol
Study NCT02990754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity education
Description: Instruction in suitable physical activity options and education about physical activity with CHD.
Study NCT03368768 — intervention group
Intervention type: OTHER
Intervention: Obtain inform consent via questionnaire of Monkey Survey
Description: This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
Study NCT02229812 — intervention group
Intervention type: DRUG
Intervention: alteplase
Study NCT00228384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE VIABAHN Endoprosthesis
Description: Implantation
Study NCT00228384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Nitinol Stent
Description: Implantation
Study NCT01168544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: loading dose Vitamin D and 50.000 IU vit D3/month
Description: loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
Study NCT01168544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: loading dose and 25.000 IU vit D3/month
Description: loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
Study NCT01168544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 800 IU /day
Description: 800 IU vit D3/day
Study NCT03500393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely Supervised Exercise (REM)
Description: REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
Study NCT03500393 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised Exercise (UNSUP)
Description: The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
Study NCT02234778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TGI SVF material via intramuscular injection
Description: Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
Study NCT01823536 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
Description: Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Study NCT02336048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
Study NCT02336048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
Study NCT02336048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
Study NCT02336048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
Study NCT02336048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Premedication
Description: Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
Study NCT02336048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Premedication
Description: Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
Study NCT02336048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
Study NCT03199742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized App Coaching
Description: All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
Study NCT03199742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
Study NCT00430391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD Consent
Description: Participants are randomized to DVD enhanced consent that is either high risk or low risk.
Study NCT00430391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Control
Description: Participants are assigned to the routine, standard consent.
Study NCT02915640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote technology
Description: Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
Study NCT03572153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Hypnosis
Description: Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
Study NCT02565693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT03572153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered White Noise Hypnosis
Description: Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
Study NCT04206670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Home Technology System and Questionnaires
Description: Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
Study NCT04206670 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Waiting Control In-Home Technology System and Questionnaires
Description: Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
Study NCT02936011 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CTO PCI using Absorb Bioresorbable Vascular Scaffolds
Description: CTO PCI
Study NCT02831608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Study NCT02517983 — intervention group
Intervention type: OTHER
Intervention: epidemiology
Description: Relative prevalence of different chronic respiratory disease phenotypes
Study NCT02416401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Study NCT02416401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study NCT02439138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1101
Description: Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
Study NCT02565693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin
Study NCT02565693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carbasalate calcium
Study NCT02565693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Study NCT04659161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
Study NCT04659161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules twice a day (BID)
Study NCT01926236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Symptom Control
Description: Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
Study NCT01926236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Symptom Control
Description: Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
Study NCT01926236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-folinic acid
Description: L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
Study NCT01926236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
Study NCT01926236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
Study NCT02746744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion of Mabthera/Rituximab every 6 months
Study NCT02746744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl fumarate
Description: Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
Study NCT02746744 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dimethyl fumarate
Description: Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
Study NCT02746744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride solution
Description: Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
Study NCT02746744 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium Chloride solution
Description: Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
Study NCT03168555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid
Description: 1250 mg CDCA is given with a study meal
Study NCT01985919 — intervention group
Intervention type: OTHER
Intervention: Obtaining human tissue for basic research or biospecimen bank
Study NCT02229253 — intervention group
Intervention type: DRUG
Intervention: degarelix
Study NCT03797508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasound
Description: To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
Study NCT01053403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine or Placebo
Description: 1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
Study NCT03498976 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulsed radiofrequency
Description: Echoguided technic
Study NCT00704431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-480848 (darapladib)
Description: 160 mg darapladib
Study NCT04373707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg
Study NCT00820560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839
Description: INCB007839 100 or 200 mg/dose as IR capsules
Study NCT04373707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
Study NCT02095990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroquinone
Study NCT02565693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dipyridamole
Study NCT02095990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02670850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Caregiver Intervention Program
Description: Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
Study NCT02565693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No antithrombotic treatment
Study NCT01065285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evaluation of vaccines against flu
Description: evaluate efficacy and tolerance
Study NCT00871936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLx-4090
Description: SLx-4090
Study NCT00871936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: matching tablets
Study NCT00871936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT04260152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Fibro-Gide
Description: Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
Study NCT02831608 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00871936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Study NCT04144049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT921
Description: Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Study NCT04144049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Study NCT04260152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective Tissue Graft (CTG
Description: Surgical recession root coverage with coronally advanced flap in combination with CTG
Study NCT02937883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowerment intervention
Description: Empowerment intervention for persons with young onset dementia
Study NCT04504539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mOPV
Description: mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1